All AbMole products are for research use only, cannot be used for human consumption.
Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer.
| CAS Number | 1418731-10-8 |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Xin Song et al. Drugs Today (Barc). Tisotumab vedotin for the treatment of cervical carcinoma
[2] No authors listed. Am J Health Syst Pharm. Tisotumab Vedotin-tftv
[3] Anthony Markham. Drugs. Tisotumab Vedotin: First Approval
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Ulocuplumab-MMAE
Ulocuplumab-MMAE is an antibody-drug conjugate (ADC). |
| Lorvotuzumab-MMAE
Lorvotuzumab-MMAE is an antibody-drug conjugate (ADC). |
| Anetumab-MMAE
Anetumab-MMAE is an antibody-drug conjugate (ADC). |
| Praluzatamab-MMAE
Praluzatamab-MMAE is an antibody-drug conjugate (ADC). |
| Oregovomab-MMAE
Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
